Sudden deafness accompanied by tinnitus
Conditions
Interventions
Standard Treatment plus Cognitive Behavioral Therapy Group:The standard treatment regimen includes: intravenous infusion of Jinnado 87.5 mg once daily, Batroxobin (1 mL on day 1, followed by 0.5 mL on
starting from the fourth session, follow-ups may be conducted by phone based on the patient’s condition. The total treatment duration is three months, but may be terminated early if tinnitus resolves
Standard Treatment Group:Jinnado 87.5 mg IV once daily, Batroxobin 1 mL IV on day 1 followed by 0.5 mL every other day (on days 3, 5, 7, and 9), oral prednisone (40 mg for 3 days ? 30 mg for 3 days ?
Sponsors
People's Hospital of Deyang city
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Those aged 18 to 75 who can cooperate to complete all test items; 2.Those who meet the diagnostic criteria for sudden deafness accompanied by tinnitus should refer to the "Guidelines for the Diagnosis and Treatment of Sudden Deafness 2015"; 3. Complete data; 4. Those with normal cognitive function at the time of enrollment (Brief Mental State Examination (MMSE) score > 17 points for the illiterate group, > 20 points for the primary school group, and > 24 points for the secondary school or above group); 5.Patients and their families voluntarily sign the informed consent form; 6. Patients who can accept this study and persist in it for a long time.
Exclusion criteria
Exclusion criteria: 1.Those with hearing loss or tinnitus caused by trauma or other systemic diseases; 2.Ear canal obstruction or diseases causing external auditory canal obstruction, physiological and anatomical abnormalities of the ear, space-occupying lesions in the inner ear, acoustic neuroma, etc; 3. Medically unstable diseases (such as cancer, stroke, cardiovascular disease, chronic obstructive pulmonary disease and severe mental illness); 4.People with mental disorders or cognitive impairments, those diagnosed with anxiety, depression, etc. before tinnitus occurs, and those using related medications; 5.Those who have recently experienced severe dizziness attacks; 6. Incomplete general information or withdrawal from this researcher halfway; 7. Participants in any other psychological intervention trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini-Mental State Examination (MMSE);Tinnitus Disability Scale (TDS);Visual Analog Scale (VAS);Self-Rating Anxiety Scale (SAS);Pittsburgh Sleep Quality Index (PSQI); | — |
Countries
China
Contacts
Public ContactMeng Sha
People's Hospital of Deyang city
Outcome results
None listed